Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States

详细信息    查看全文

• 作者：Jieling Chen (3)
  Megan A. O’Brien (2)
  H. Keri Yang (2)
  John D. Grabenstein (2)
  Erik J. Dasbach (1)
  
• 关键词：Cost ; effectiveness ; Health outcomes ; Pneumococcal vaccination ; Quality ; adjusted life ; year ; Vaccine effectiveness
• 刊名：Advances in Therapy
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：31
• 期：4
• 页码：392-409
• 全文大小：
• 参考文献：1. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-.
  2. Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50?years and older. MMWR Morb Mortal Wkly Rep. 2012;61:394-.
  3. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-4.
  4. Fedson D, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011;10:1143-7. CrossRef
  5. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:c1004. CrossRef
  6. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine. 2004;22:927-6. CrossRef
  7. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;CD000422.
  8. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48-8. CrossRef
  9. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307:804-2. http://www.ncbi.nlm.nih.gov/pubmed/22357831.
  10. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis 2008;14:267-4.
  11. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ?0?years. Vaccine. 2012;30:5437-4. CrossRef
  12. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955-0. CrossRef
  13. Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21:303-1. CrossRef
  14. Centers for Disease Control and Prevention. Vaccines for Children Program (VFC). Archived CDC vaccine price list as of September 10, 2012. http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/2012/2012-09-10.html. Last accessed October 6, 2013.
  15. Bureau of Labor Statistics, United States Department of Labor, Crawford M, Church J, Rippy D. (eds.). CPI detailed report data for December 2012. http://www.bls.gov/cpi/cpid1212.pdf. Last accessed March 17, 2014.
  16. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices, summary report, June 20-1. Atlanta: Centers for Disease Control and Prevention; 2012. http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun12.pdf. Last accessed October 6, 2013.
  17. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-1. CrossRef
  18. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-6. CrossRef
  19. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309-0. CrossRef
  20. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine. 2012;30:4435-4. CrossRef
  21. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-8. CrossRef
  22. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. US hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155-3. CrossRef
  
• 作者单位：Jieling Chen (3)
  Megan A. O’Brien (2)
  H. Keri Yang (2)
  John D. Grabenstein (2)
  Erik J. Dasbach (1)
  
  3. Merck Sharp & Dohme R&D, Beijing, China
  2. Merck, West Point, PA, USA
  1. Merck, North Wales, PA, USA
  
• ISSN：1865-8652

文摘

Introduction In 2012, the Advisory Committee on Immunization Practices (ACIP) revised recommendations for adult pneumococcal vaccination to include a sequential regimen of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for certain high-risk adults with immunocompromising conditions. This study, from a payer perspective, examined: (1) the cost-effectiveness of the new 2012 ACIP vaccine policy recommendation relative to the 1997 ACIP recommendation; (2) the cost-effectiveness of potential future pneumococcal vaccination policies; and (3) key assumptions that influence study results. Methods A static cohort model that incorporated costs, health outcomes, and quality-adjusted life-year (QALY) losses associated with invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia (NBPP) was developed to evaluate seven pneumococcal vaccination strategies for a 50-year-old adult cohort over a 50-year period using incremental cost-effectiveness ratios (ICERs). Results For objective 1, the 2012 ACIP recommendation is the more economically efficient strategy (ICER was $25,841 per QALY gained vs. no vaccination). For objective 2, the most efficient vaccination policy would be to maintain the 2012 recommendation for PPSV23 for healthy and immunocompetent adults with comorbidities, and to modify the recommendation for adults with immunocompromising conditions by replacing PPSV23 with a sequential regimen of PCV13 and PPSV23 at age 65 (ICER was $23,416 per QALY gained vs. no vaccination). For objective 3, cost-effectiveness ratios for alternative pneumococcal vaccine policies were highly influenced by assumptions used for vaccine effectiveness against NBPP and accounting for the herd protection effects of pediatric PCV13 vaccination on adult pneumococcal disease. Conclusion Modifying the 2012 recommendation to include an additional dose of PCV13 at age 65, followed by PPSV23, for adults with immunocompromising conditions appears to be a cost-effective vaccine policy. Given the uncertainty in the available data and the absence of key influential data, comprehensive sensitivity analyses should be conducted by policy-makers when evaluating new adult pneumococcal vaccine strategies.